BioIQ, a healthcare technology company driving the shift to value-based care, announced today it has raised $26.5M. The financing was led by HealthQuest Capital, with Arboretum Ventures and select insiders joining the syndicate. BioIQ will use the funding to fuel continued growth and support its mission to help transform the U.S. healthcare system and impact more than 100 million lives.
Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire NxThera, a privately-held company based in Maple Grove, Minnesota. NxThera developed and commercialized, in the United States (U.S.) and Europe, the Rezūm® system which is a minimally invasive therapy in a growing category of treatment options for men with symptoms arising from of benign prostatic hyperplasia (BPH).
Twin Cities med-tech company NxThera to be sold to Boston Scientific in $400M deal
Twin Cities med-tech company NxThera Inc. has agreed to be sold to Boston Scientific Corp. in a deal worth up to about $400 million, the companies announced Wednesday.
Maple Grove-based NxThera also will spin out a yet-to-be-named startup as part of the deal. The new company will pursue regulatory approval of NxThera’s device as a treatment for prostate cancer, NxThera CEO Bob Paulson said.
A new category of prescription medical treatments, what executives call digital therapeutics, comes in the form of mobile apps. Health tech companies are making a big push to digitize medicine, introducing novel tools like digital pills that track when patients take their drugs and smart spoons that can automatically adjust to hand tremors.
NxThera, Inc., a medical device company pioneering the application of its Convective Water Vapor Energy (WAVE®) platform technology to treat endourological conditions, announced study findings that demonstrate its Rezūm® System provides effective and durable improvements in benign prostatic hyperplasia (BPH) symptom scores with clinical progression rates five times lower when compared to daily, long-term use of pharmaceutical agents three years after treatment.
Strata Oncology, a precision oncology company, today announced that Aurora Health Care, the largest healthcare system in Wisconsin, and University of Texas Health Sciences at Houston (UTHealth) have joined the Strata Precision Oncology NetworkTM (Network).
NxThera, Inc., a medical device company pioneering the application of its Convective Water Vapor Energy (WAVE®) technology to treat endourological conditions, today announced the launch of the Rezūm® Center of Excellence program recognizing top urologists across the country for their expertise in treating benign prostatic hyperplasia (BPH), or enlarged prostate.
PEAR Therapeutics announced today that it has entered into a collaboration with Novartis to develop novel prescription digital therapeutics for schizophrenia and multiple sclerosis (MS). These digital therapeutics are software applications designed to effectively improve clinical outcomes for patients. The collaboration brings together Novartis’ expertise in neurological disorders, clinical development, and commercialization with PEAR’s leading experience in prescription digital therapeutic design and implementation.
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Advanced ICU Care, the largest provider of tele-ICU care in the U.S., has extended its collaboration with Philips by signing a new 12-year agreement. A Philips tele-ICU customer since 2006, Advanced ICU Care will leverage Philips’ tele-ICU technology to help power nine virtual care hubs, monitoring nearly 1,000 ICU beds across the U.S.
NxThera, Inc., a medical device company pioneering the application of its Convective Water Vapor Energy (WAVE®) technology to treat endourological conditions, today announced publication of a recent economic analysis which demonstrates its minimally invasive Rezūm System to be a cost-effective and durable solution in treating benign prostatic hyperplasia (BPH).
Magellan Health, Inc. (NASDAQ: MGLN) has long been the national leader in the use of digital innovation to help those struggling with various medical and behavioral conditions, including Substance Use Disorders (SUD). As a pioneer in the use of digital therapeutics and computerized cognitive behavioral therapy (CCBT), Magellan has engaged in a new initiative designed to measure clinical outcomes in patients with SUD by leveraging reSET®, the first ever FDA cleared prescription digital therapeutic from PEAR Therapeutics.
No more posts to load.
Load More Posts